However like any other drug, HQ does have its share of side effects. In the 1980’s, the most commonly reported complication was disfiguring exogenous ochronosis or pseudo-ochronosis which presents as dark discolorations and grey-blue bumps on sun-exposed areas of the skin. Other reported side effects include loss of skin elasticity, poor wound healing, skin nodules appearing especially on the upper back and nail discoloration. Most, if not all of these side effects, stem from the improper use and the use without the supervision of a dermatologist of HQ on large areas of the face and body for a prolonged period of time.

What has largely contributed to the misuse of HQ? Consumers in their desire to have that flawless, fair skin have resorted to applying high concentrations of HQ over large areas of the face and body for a period of several months to years.  Unethical practices by some manufacturers compounded the problem such as the lack of ingredient labeling or inaccurate concentrations of HQ indicated in the product. From the usual concentrations of 2 – 4 %, HQ concentrations of 6- 8.5% have been used.  Also, to disguise the incorporation of HQ in a skin product, synonyms like “1,4-benzenediol”  or  “p-diphenol” were used instead.  The lack of regulating bodies or clear guidelines in some countries has also resulted in cosmetic and toiletry products containing HQ to flood the retail shops and market places aggravating its unsupervised use.

All these have unfortunately compromised the safety of using HQ which has been part of the therapeutic armamentarium of physicians in treating hyperpigmentation. There now exists a real health concern of new side effects being noted more in patients if these practices would be allowed to continue and proliferate.

It is for this reason that in the Philippines, the PDS recommends the regulated use of HQ as proposed by the Bureau of Food and Drugs (BFAD). All preparations containing less than or equal to two percent (2%) HQ can be dispensed without the supervision of a licensed pharmacist.  Preparations containing more than two percent (2%) but less than or equal to four percent (4%) HQ must be dispensed under the supervision of a licensed pharmacist. Preparations containing more than more than four percent (4%) but less than five percent (5%) HQ must be dispensed only by licensed pharmacists of registered drug outlets upon the presentation of a proper prescription.  Furthermore, to help prevent the abuse of HQ usage, the PDS supports efforts moving for a stricter regulation on HQ-containing products as proposed by the BFAD, such as making all concentrations of HQ available only upon the presentation of a proper prescription.

REFERENCES

Ly, Fatimata, Anta Soumare Soko, et al. “Aesthetic problems associated with the cosmetic use of bleaching products.” International Journal of Dermatology 46 (2007): 15-17.

Olumide, Yetunde M., Ayesha O. Akinkugbe, et.al. “Complications of chronic use of skin lightening cosmetics.” International Journal of Dermatology 47 (2008): 344-353.

Westerhof W., T J Kooyers. “Hydroquinone and its analogues in dermatology- a potential health risk.” Journal of Cosmetic Dermatology 4 (2005): 55-59.

McGregor, Douglas. “Hydroquinone: An Evaluation of the Human Risks from its Carcinogenic and Mutagenic Properties.” Critical Reviews in Toxicology 37 (2007): 887-914.

Toombs, Ella L. “Hydroquinone-what is it’s future?” Dermatologic Therapy 20 (2007): 149-156.

Nordlund,JJ, PE Grimes, JP Ortonne. “The safety of hydroquinone.” Journal of the European Academy of Dermatology and Venereology 20 (2006): 781-787.

Levitt, Jacob. “The safety of hydroquinone: A dermatologist’s response to the 2006 Federal Register.” JAAD 10.1016 (2007):854-872.

Draelos, Zoe Diana. “Skin lightening preparations and the hydroquinone controversy.” Dermatologic Therapy 20 (2007): 308-313.

The Importance of Using a Sunscreen Everyday

Evelyn R. Gonzaga, MD, FPDS, FAAD

Sunlight and exposure to the elements can cause damaging and unwanted stresses on the skin. In fact how old our skin looks is often dictated by environmental aspects especially ultraviolet light radiation (UVR).

So what is UVR and where does it come from? Sunlight is composed of a continuous spectrum of electromagnetic radiation that is divided into three main parts: ultraviolet light (UV) 5%, visible light 50% and infrared 45%. UV light is further divided into three subgroups namely UVC, UVB and UVA. UVC is absorbed by the ozone layer and does not reach the ground. UVB is the primary cause of sunburn and skin cancer. UVA, on the other hand, represents 90% of the total UVR reaching the earth’s surface, penetrates deeper into the skin to cause skin darkening, and penetrates most deeply into the eyes and can cause retinal degeneration. UVA is twenty times more abundant than UVB, and is present all day and throughout the year and can reach the skin even through windows.

Consequences of sun exposure include sunburn, tanning, darkening of freckles, premature aging or photoaging of the skin like coarse wrinkling, yellow hue, laxity, thickening and furrowing of the skin, telangiectasia, solar keratoses, cataracts, and skin cancers. (Fig. 1).

Photoaging accounts for most age-associated changes in skin appearance and affects lighter skinned individuals most severely and it accounts for 90% of the unwanted changes in appearance in skin. The face, neck, dorsum of the hands and forearms are most commonly affected.

Clinical Picture of Photoaged Skin includes: wrinkles, yellow hue, laxity, telangiectasia, leathery appearance and skin cancer (Fig.1)

So how do we protect our skin from Photoaging? Photoprotection is the single most cost-effective therapy for photoaging. It includes sun avoidance, wearing protective clothing and the use of sunscreens. Sun avoidance includes limiting exposure during peak UV times, particularly between 10am and 4pm, avoiding UV- reflective surfaces such as the sand and water. Physical protection includes wearing photoprotective clothing such as a broad-brimmed hat 4 inches or greater, wearing long sleeves clothes, use of dark colored umbrellas and use of UV-blocking films on windows.

The use of sunscreen products has been advocated by the dermatologists as a means to reduce skin damage produced by ultraviolet radiation from sunlight.

What sunscreen should you use? Sunscreens prevent photodamage and allows repair of the skin. These products represent an extension and an increase of the skin’s natural defense mechanisms against UVR. The term “sunblock” is commonly used to refer to sunscreen and their active ingredients. Today the US Food and Drug Administration sunscreen monograph does not sanction the term because the consumers might be misled into thinking that the product completely blocked all sunlight.

Is SPF enough in a sunscreen?

The Sun Protection Factor (SPF) scale specified in a sunscreen product applies solely to UVB protection – so it provides inadequate photoprotection.as it does not give you enough protection against UVA rays as well. Below are the SPF guidelines:

4 Categories of UVB sunburn protection products:

Low SPF 2 to <15

Medium SPF 15 to <30

High SPF 30 to 50

Highest SPF >50

The ideal sunscreen should contain organic or inorganic ingredients that act as UV absorbers and UV reflectors. The combination of UVB and UVA filters contained in the sunscreen will provide broad-spectrum photoprotection. Your dermatologist can provide you with this information.

The UVA Sunscreen Rating is the Star System. The rating is as follows:

UVA Rating                     Persistent Pigment Darkening

Low 1*                             2 – < 4 hours

Medium 2**                     4 – < 8 hours

High 3***                         8 – < 12 hours

Highest 4****                  12 or above

Good Protection is 4 Stars

In short, when choosing a sunscreen – look for one that has both UVB and UVA protection. It is best to consult your dermatologist when making this choice.

How much sunscreen should you apply?

Most people only use 0.5mg/cm^{2 to} 1mg/cm² , which is 25% to 50% of the recommended dose. The ideal dose of application is actually 2mg per cm² (square centimeter) of the body^. and a simple way of making sure you have the right dose is called the “Teaspoon Rule of Sunscreen Application” (Fig. 2)

Fig 2. Teaspoon Rule of Sunscreen Application

Sunscreens containing both UVA and UVB filters should be used daily. The amount to be applied should be more than half a teaspoon each on head and neck and each arm, and more than a teaspoon each on anterior torso, posterior torso and each leg.

When should sunscreens be applied?

Sunscreens should be applied to exposed areas 15 to 30 minutes before going out into the sun. Reapply to exposed sites 15 to 30 minutes after sun exposure begins and further reapplication is advised every 2-4 hours after vigorous activity that remove sunscreen such as swimming, toweling or excessive sweating and rubbing.

What are the sunscreen preparations available for your use?

Sunscreens are available in a variety of preparations. Lotions are the most popular preparations. Creams are more water resistant and provide higher SPF protection. Gels are non-greasy, good for oily skin or when sweating. Sticks are the most water resistant, good for the lips or around the eyes and best for sensitive skin. Aerosols are best on the body.

In light of the numerous benefits of broad-spectrum photoprotection, daily use of sunscreens is advocated by members of the Philippines Dermatological Society as well as by the dermatologists worldwide.

In summary, the Regimen of Overall Photoprotection includes

Sunglasses to protect the eyes

Protective clothing

Avoid midday sun

Regular use of broad spectrum (UVB & UVA) sunscreens – everyday, even if you will stay indoors!

References:

1. Gasparro FP, Mitchnick M, Nash, JF. A review of sunscreen safety and efficacy, Photochemistry and Photobiology 1998; 68(3):243-256

2. Kullavanijaya P, Lim HW. Photoprotection, J Am Acad Dermatol 2005; 52:937-58

3. Baron ED, Kirkland EB, Domingo, DS. Advances in Photoprotection, Deramtol Nurs. 2008; 20(4):265-273

4. Rabe JH, Mamelak AJ, McElgunn, JS et al. Photoaging: Mechanisms and repair, J Am Acad Dermatol 2006, 55:1-19

5. Gonzaga, ER. Role of UV light in photodamage, skin aging and skin cancer, Am Journal of Clinical Dermatology 2009, vol 10 suppl.1:1-24

6. Berneburg M, Plettenberg H, Krutmann J. Phoaging of human skin, Photodermatol PhotoImmunol Photomed  2000: 16:239-244

7. Wang SQ, Stanfield JW, Osterwalder U. In vitroassessments of UVA protection by popular sunscreens available in the United States, J Am Acad Dermatol 2008, 59:934-42

8. Moyal D. How to measure UVA protection afforded by sunscreen products, Expert Rev Dermatol 2008; 3(3):307-313

9. Yaar M, Gilchrest BA. Photoaging: mechanism, prevention and therapy, British Journal of Dermatology 2007, 157:874-887

10. Gilchrest BA. The A – B – C – Ds of Sensible Sun Protection, http://www.medscape.com/viewarticle/578334

11. Pinnell SR. Cutaneous photodamage, oxidative stress, and topical antioxidant protection, J Am Acad Dermatol 2003;48:1-19

12. Lim HW, Naylor M, Honigsmann H, Gilchrest BA, Cooper K, Morison W, Deleo, VA. American Academy of Dermatology Consensus conference on UVA protection of sunscreens: summary and recommendations, J Am Acad Dermatol 2001, 44(3):505-508

13. Svobodova A, Walterova D, Vostalova J. Ultraviolet light induced alteration to the skin, Biomed Pap Med Fac Palacky Olomouc Czech Repub. 2006, 150(1):25-38

14. Matts PJ. Solar ultraviolet radiation: terminology and terminology. Dermatol Clin 2006, 24:  1-8

15. Lowe, NJ. An overview of ultraviolet radiation, sunscreens and photo-induced dermatoses, Dermatol Clin 2008, 24: 9-17

16. Maloney FJ, Collins S, Murphy GM. Sunscreens: safety, efficacy and appropriate use, Am J Clin Dermatol 2002, 3(3)185-191

17. Pruim B, Green A. Photobiological aspects of sunscreen reapplication, Australasian Journal of Dermatology 1999, 40:14-18

18. Lautenschlager S, Wulf HC, Pittelkow MR. Photoprotection, www.thelancet,com. Published online may 3, 2007

19. Antoniiou C, Katsambas AD. Sunscreens – What’s important to know, JEADV 2008, 22:1110-1119

20. Green A, Lancet 1999; 3345:723-729

21. Tuchinda C, J Am Acad Dermatol 2006; 54:845-54

22. Lautenschlager S. Published online May3, 2007 Triemli Hospital, Zurich, Switzerland

23. Rabe HR, J Am Acad Dermatol 2006;55:1-19

24. Draelos ZD, Cosmetic Dermatol 2003;16,8:63-68

25. Wulf HC, Stender IM et el J Am Acad Dermatol 2003;48:1-19

26. Archives of Dermatol, June 2002 Vol 138 No. 6

27. Diffey BL, J Am Acad Dermatol 2001;45:882-885

It is most unfortunate that the Philippine Dermatological Society has been misquoted and statements taken out of context.

The Philippine Dermatological Society recommends the regulated use of Hydroquinone (HQ) as proposed by the Bureau of Food and Drugs (BFAD). All preparations containing less than or equal to two percent (2%) HQ can be dispensed without the supervision of a licensed pharmacist.  Preparations containing more than two percent (2%) but less than or equal to four percent (4%) HQ must be dispensed under the supervision of a licensed pharmacist. Preparations containing more than four percent (4%) but less than five percent (5%) HQ must be dispensed only by licensed pharmacists of registered drug outlets upon the presentation of a proper prescription.  Furthermore, to help prevent the abuse of HQ usage, the PDS supports efforts moving for a stricter regulation on HQ-containing products as proposed by the BFAD, such as making all concentrations of HQ available only upon the presentation of a proper prescription.

For further information, please read the entire article found on our website entitled “Unsupervised Hydroquinone Use: Beware of what you put on your skin”, as published in the Philippine Daily Inquirer on November 12, 2009.

For the Board of Directors,

Dr. Georgina C. Pastorfide, FPDS
President
Philippine Dermatological Society

Satellite Meeting 2009

19 Jalan Folly Barat, 50480 Kuala Lumpur, Malaysia

Tel: (603) 2093 0100, 2093 0200

Fax: (603) 2093 0900

Email: secretariat@asianderm.org

CONFERENCE VENUE

Hilton Hanoi Opera Hotel

1 Le Thanh Tong Street,Hoan Kiem Dist,Hanoi,Vietnam

Tel:84-4-39330500

Fax:84-4-39330530

REGISTRATION FORM

Please return the completed Registration Form to the Congress Secretariat with appropriate fees before 30^th August 2009 to ensure receipt of the conference bag and the complete set of conference materials upon checking in at the Conference Registration Desk. Photocopies of the form may be used.

REGISTRATION FEES

REGISTRATION FEES PAYMENT

All payments are to be issued in favour of the “Satellite Meeting 2009”.

HOTEL ACCOMMODATION

The Organizing Committee has negotiated for special rates with the conference hotel, Hilton Hanoi Opera Hotel, Hanoi, Vietnam.

Room Type Room Rate

Deluxe Single Room USD 175 per room per night (inclusive of daily buffet breakfast)

Deluxe Twin/Double Room USD 190 per room per night (inclusive of daily buffet breakfast

On-site Registration 1000 Asian Dermatology Summit (Asean 5 + 5): ”Asian Dermatology – Moving Forward”

• Introduction and welcome by Chairman – Globalization and its impact on Asian dermatology

• Disparities in dermatology care delivery in Asia – Gap Analysis,Challenges and Opportunities

• Dermatology training in North Asia

• Harmonizing of dermatology training in ASEAN – Taking the first step

• Experiences of other international dermatological societies

• Asean Free Trade Agreement (AFTA/MRA) – Implications to the practicing dermatologists

• Summary and Conclusion AFTERNOON 1200 Business Meeting of LADS/AADV (Lunch) 1400 ASIAN PSORIASIS FORUM

– BIOLOGICS THERAPY STUDY GROUP

Biologics in Asia – A review of what’s around?

Pharmaco-economics of biologic therapy – The European experience

Long-term safety issues in biologics
Towards developing an Asian Consensus for Biologic Treatment – Panel discussion 1530 ASIAN HAIR FORUM (SESSION 1)

– ADVANCES IN HAIR SCIENCE AND RESEARCH IN ASIA 1530 W O R K S H O P

SHARING EXPERIENCES IN TOPICAL TREATMENT OF PSORIASIS 1800 FACULTY DINNER (By invitation only)

AADV Inauguration/St Johns’ Alumni (Asia) Night Day 2 6th November 2009 Friday 0700 REGISTRATION 0800 OPENING CEREMONY Introduction by MC

Welcome Address by Chairman, International Organizing Committee

Welcome Address by President, Vietnam Dermatological Society

Opening Speech by Guest of Honor 0900 Opening and Official Tour of Trade Exhibition

Press Conference 1000 PLENARY SESSION 1

1. The genetics and immuno-pathology of psoriasis – Implications for antipsoriatic treatment

2. The molecular basis of cutaneous inflammation in atopic dermatitis – Update 2009

3. Skin disease – Socioeconomic implications to Asian communities 1130 SYMPOSIUM 1

Managing Difficult Psoriasis – 10 minute snippets

1. Psoriatic erythroderma – What’s new in management?

2. Co-morbidities and mortalities in psoriasis

3. Psoriasis in patients with HIV disease

4. Psoriasis in Pregnancy

5. Metabolic syndrome in psoriasis 1130 SYMPOSIUM 2

Atopy, Allergies & Allergens

1. Atopic dermatitis – Clinical epidemiology in Asia

2. Allergic contact dermatitis – Asian perspective

3. Dealing with facial dermatitis in atopics and complications from aesthetic treatment

4. Making Calcineurin inhibitors for atopic dermatitis cost-effective 1130 SYMPOSIUM 3 (ASIAN HAIR FORUM SESSION 2)

Scaly Scalp and Hair Disorders

1. Alopecia in scalp psoriasis

2. Scalp diseases in childhood

3. Contact dermatitis of the scalp

4. Pathogenic role of Pityrosporum ovale in scalp diseases 1300 LUNCH SYMPOSIUM 1

An exclusive event by P&G Beauty & Grooming

“A trilogy of science, skin health and beauty” 1430 PLENARY SESSION 2

Is anti psoriatic monotherapy sustainable?

1. Use of systemic retinoids – Past, present and future

2. A re-look at older systemic immune-modulators

3. Update on topical treatment for psoriasis 1530 SYMPOSIUM 4

Cosmeceuticals Symposium

Helping your patients look good and feel good

1. Delivering the promise of cosmeceuticals science to your patients

2. Rejuvenating the tired skin – What can science offer

3. Dealing with recalcitrant dandruff and “bad hair days”

4. Sunscreens for Asian skin 1530 SYMPOSIUM 5

QoL issues in skin diseases

1. Measuring disease severity – The Asian context

2. Adapting QoL indices for your patients

3. Does treatment improve your patient’s QoL – What the data says? 1530 SYMPOSIUM 6

Basic Dermatopathology – Diagnostic Pearls

1. Differentiating common dyskeratotic skin diseases – The ABC

2. Usual and unusual histopathology findings in psoriasis

3. Chronic eczema and non-specific dermatitis

4. Histopathological differential diagnosis of alopecia 1630 SYMPOSIUM 7

New Strategy in Psoriasis treatment – Targeting the IL12 & 23 Pathway 1930 A NIGHT OUT IN HANOI (Free & Easy) Day 3 6th November 2009 Saturday 0800 BREAK FAST DIALOGUES

Speak to your experts

BD 1 • Dilemmas in choosing biologics

BD 2 • How to deal with intractable chronic urticaria?

BD 3 • The scaly scalp – Sorting out the flakes (Asian Hair Forum Session 3)

BD 4 • Dealing with chronic stress and psycho-social issues in chronic psoriasis

BD 5 • Rationalizing topical treatment for psoriasis 0900 PLENARY SESSION 3

Psoriasis Panorama

1. Psoriasis phenotypes and the antigens in psoriasis – Opportunities for intervention

2. Psoriatic and other inflammatory arthritis – The new DMARDs

3. Counseling and family issues in psoriasis – What the genes say 1030 WORKSHOP 1 ( “ HOW I DO IT ? ” )

Managing the child with difficult eczema

1. Emollients and wet dressing

2. Choosing antihistamines for children

3. Making topical immune-modulators more cost-effective

4. Shifting out the nonsense – What doesn’t work? 1030 WORKSHOP 2

Practical tips in allergy management

1. How is sense and nonsense in allergy testing?

2. How I manage the child with food allergies?

3. House dust mite allergy – Can anything be done?

4. Sorting out drug allergies in patient with multiple prescriptions – The ABC 1030 WORKSHOP 3

Clinical Epidemiology of Psoriasis in Asia presented by Asian Psoriasis Forum Working Group

1. Psoriasis and skin diseases in Vietnam

2. Psoriasis treatment and the risk of infection, cancers and lymphomas – A review existing data

3. Traditional and unorthodox treatments and its impact on disease pathogenesis

4. Building an Asian Psoriasis Register – Moving Ahead (Panel Discussion) 1030 WORKSHOP 4

Innovations in Hair Care for Patients (Asian Hair Forum Session 3)

1. The science of shampoos and conditioners

2. Characteristics of Asian scalp and hair

3. How to choose the right shampoo and scalp treatment agents for your patients 1130 T E A / C O F F E E 1200 LUNCH SYMPOSIUM 3 ( INDUSTRY – SPONSORED )

The pharmacoeconomics of long-term topical treatment in Psoriasis LUNCH SYMPOSIUM 4 ( INDUSTRY SPONSORED )

Antihistamine guidelines – Therapeutic strategies 1430 FREE PAPERS / POSTER PRESENTATIONS 1430 CLINICO-PATHOLOGY PRESENTATION ( VIRTUAL GRAND ROUNDS DERMATOLOGY, VGRD)

A selection of four unusual clinical cases from the VGRD 1600 PLENARY 4 – “ WHAT’S NEXT ? ”

1. Expanding role of biologics in skin diseases

2. Topical Immuno-modulators – Future options

3. Therapeutic innovations for scalp diseases

4. New Era of Dermatology in Asia – The LADS / AADV Vision

5. WCD 2011 – Korea Welcomes You

6. Closing Remarks by Chairman, LOC 1730 T E A / C O F F E E

End of Conference 1930 Congress Dinner:

LADS / AADV – P & G BEAUTY & GROOMING GALA DINNER

“A Night @ the Opera”

Venue: Hanoi Opera House

P O S T – C O N G R E S S

]]> http://pds.org.ph/programme-schedule/feed/ 0 http://pds.org.ph/message-from-the-organising-chairman-secretary-general-ladsaadv/ http://pds.org.ph/message-from-the-organising-chairman-secretary-general-ladsaadv/#comments Mon, 14 Sep 2009 13:15:56 +0000 admin http://pds.org.ph/?p=504 It is my pleasure and honor to invite you to the Satellite Meeting 2009 organized by the League of Asean Dermatological Societies (LADS) hosted by the Dermatological Society of Vietnam. This special event will also mark the inaugural meeting of the Asian Academy of Dermatology and Venereology (AADV) which has been spearheaded by the members of LADS

We are indeed proud to bring this important and prestigious scientific meeting to welcome our Vietnamese colleagues into this important regional fraternity

As in other major regions of the world, the specialty of dermatology has come of age in Asia. The LADS was made significant strides over the last few years and will continue to evolve and grow with the formation of the AADV

This Satellite Meeting 2009 presents a unique opportunity for the dermatological profession in Asia to come together in fraternity and fellowship to review the latest developments and breakthroughs in two important areas of dermatology, namely psoriasis and eczema. It will provide our dermatologists with a platform to exchange experiences and ideas in clinical practice and research.

This conference will not only provide a platform for knowledge exchange among our colleagues in Asia but will also pave the way for enhanced regional and international cooperation in the field of dermatology.

I am confident that you will find this Satellite Meeting 2009 an excellent educational and memorable experience

On behalf of the Organising Committee I bid you a warm welcome to Hanoi.

Steven K W Chow
Chairman
International Organising Committee
Secretary-General LADS/AADV

Thank you for the encouraging comments we have received regarding the television and radio commercials. The radio commercials will be aired again in September and we will be sending you the schedule later this month.

As part of the Skin Safety Campaign (SSC), a 4-panel colored brochure on basic information on the skin, hair and nails was prepared by the SSC Task Force. This was made possible through an educational grant from Unilever Philippines. The brochures were distributed to one (1) million public high school students as part of information dissemination. One hundred (100) free copies for each member in good standing are available for pick up at the PDS office. The bundled brochures are heavy and the mailing cost is prohibitive. We will be bringing some of the brochures to the August 26 CME meeting in Wack Wack Golf and Country Club. You can pick up your copies on a “first come, first serve” basis.

Available for pick up and at cost for members in good standing are more copies of the SSC door decal (P20 each) for your clinics and the SSC patient information leaflets (P100 for 100 pcs). One door decal and a bundle of the leaflets were given out free during the PDS Annual Convention last year.

Please send your requests by email (pds_org@pldtdsl.net or pds_org@yahoo.com) or call the PDS office. Only check payments will be accepted.

For our colleagues who are based in the provinces, we will bring the brochures to the Annual Convention in November.

Please email us your feedback, suggestions or concerns.

Truly yours,
Rosalina E. Nadela, MD, FPDS
Secretary

ADVISORY -

The Philippine College of Physicians through its Committee on Advocacy, Subcommittee on Pharmacovigilance, would like to warn its members and the public regarding the existence of counterfeit influenza vaccines. This is in the light of reports this last week of July of the seizure of P4 million worth of fake flu vaccines filled with distilled water and the arrest of a trader who was a former medical representative, during an operation conducted by operatives of the NBI Anti-Fraud and Computer Crimes Division (AFCCD) in San Pedro Laguna. According to officials of the Department of Health, these reports may just be the tip of the iceberg as they are now also receiving reports of some groups going around small offices to peddle supposedly approved flu vaccines at “attractive” prices.

The PCP members and the public therefore cautioned to obtain vaccines only from reputable and BFAD accredited suppliers. In a public advisory published in the major newspaper last July 28, the BFAD warns all drugstore owners and/or their pharmacist to exercise extra diligence in buying this vaccine and any other drugs. Acting BFAD Director Nazarita Tacandong wrote, “ they should buy only from sources duly licensed by BFAD and always demand sales invoices or receipts from their sources indicating therein the name of the drugs and medicines purchased and their respective lot numbers and expiry date. Refusal of the source to issue and/or indicate the aforementioned information should give rise suspicion and must be reported immediately to BFAD.”

Flu vaccines are available either as pre-filled syringe or vials. It may be difficult to distinguish the fake vaccines from the authentic vaccines but it may be possible to spot both the subtle and obvious differences. To ensure the integrity of the vaccines, check the following:

• For pre-filled syringes, the vaccines must be in a sealed packaging (carton) containing the manufacturer label and lot number. The seal is usually also printed with the name of the company and not just an ordinary tape.

• If the vaccine is in vials, ensure that the vials are the original containers and the metal crimping seal is intact and unopened.

• Check the label as some fake vaccines have labels that were printed with ordinary desktop printers that easily blot when wet or which are not as clear as the original labels.

Sanofi Pasteur also published in the major newspaper a public notice last August 02, 2009. The article in the Philippine Daily Inquirer gives the following distinguishing points between authentic and counterfeit vials.

According to the Sanofi Pasteur advertisement, the NBI has confiscated counterfeit VAXIGRIP vaccines with the following batch No. D12228, Manufacturing Date: 18-Dec-08 and Expiry Date: 18 Dec-09

In the Philippines, there are 4 brands of flu vaccine that are available in the market: Vaxigrip. Fluarix, Agrippal S1 and Influvac. Other brands of vaccines that are being sold may be suspicious. Vaccines sold at a significantly lower amount that the market price are also considered suspect. As well, the public is warned about buying these vaccines on line since it may be difficult to verify the authenticity of the source.

To report any information about fake flue vaccines, the public may call up the BFAD Hotline 842-5606, BFAD Regulation Division 809-4390 local 1131 or NBI Hotline 524-5395 and 525-4093

Dr. Annette Wagner

Hospital Affiliations

She has served as Pediatric Consultant at the Holy Cross Hospital and attending Pediatrician at Mariposa Pediatrics, Nogales Arizona.

From 1994-1998, she was director of Clinical Services, and later Clinical Practice Director of the Division of Dermatology at the Children’s Memorial Hospital, Northwestern University.

Assistant Professor of Pediatrics and Dermatology at Northwestern University’s Feinberg School of Medicine.

Presently, she is Assistant Professor of Pediatrics and Dermatology and Attending Physician at the Children’s Memorial Hospital, Northwestern University, Chicago.

Dr. Wagner sees patients at Children’s Memorial Hospital, Children’s Specialty Center in Westchester and at the Busse Specialty Center of Northwest Community Hospital in Arlington Heights.

Medical background

Bachelor of Science degree in Cell and Microbial Biology (First Class Honors) from the University of Calgary in Alberta, Canada

Obtained her Medical degree from the McGill University, Montreal, Quebec.

She finished her Pediatric Residency and Dermatology Residency in the University of Arizona, Tucson, Arizona.

Diplomate of the American Board of Pediatric Dermatology, Fellow of the American Academy of Pediatrics

Diplomate of the American Board of Dermatology and Fellow of the American Academy of Dermatology.

Honors/Awards

Considered a trailblazer in pediatric dermatologic surgery, her other special interests include pigmented and vascular birthmarks, and laser therapy and surgery.

Principal Investigator of numerous research papers focusing mainly on Hemangiomas.

Member of the Mentorship Committee of Women’s Dermatologic Society, Mentorship Task Force of the Society of Pediatric Dermatology, and Northwestern Medical School Pediatric Mentorship Program

Reviewer of several publications such as the American Journal of Clinical Dermatology, and as Grant Reviewer at the National Institutes of Health Expertise Pediatrics, Dermatology, Laser Pediatric Dermatologic Surgery.

Best Doctors in America, Midwestern Region, Who’s Who of American Women, Marquis Who’s Who America

In 2005, she became Woman of the Year of the American Biographical Institute.

———————————————————————————————-

MORNING  SESSION

7:30-8:15 am    Registration/ Breakfast

8:15-8:30 am    Invocation: Dr. Filomena Legarda.-Montinola

Opening Remarks:

Dr. Imelda Cabral-Villar

Introduction of Dr. Annette Wagner

Dr. Peachy G. Paz-Lao

8:30-9:00am     Hemangioma-What is New and What We Do

Dr. Annette M. Wagner

9:00-9:30am    Practical Laser Pearls in Children:

Dr. Annette M. Wagner

9:30-10:00am   Standard and Advances in Laser/Light Technology for

Pigmented   Lesions:  Dr. Elsie P. Floreza

10:00-10:20am Phototherapy from A – Z: Dr. Patricia  Ty-Tinio

10:20-10:40am OPEN FORUM/ BREAK

10:40-11:00am  Simplified Office Photopatch testing : Dr. Vermen Verallo-Rowell

11:00 -11:20am            Selection of Biopsy Specimens for Light Microscopy

and Immunohistopathology: Pearls and Pitfalls

Dr. Jasmin J. Jamora

11:20-11:40pm            Downers and Anesthesia for Dr. Krissy Dim-Jamora

11:40-12:00pm            OPEN  FORUM/ AWARDING OF CERTIFICATES

12:00-1:00pm  LUNCH SYMPOSIA: Stress-Related Dermatoses

Dr. Peachy G. Paz-Lao

Handling Atopics: Is It That Simple

Dr. Ma. Victoria C. Dizon

AFTERNOON  SESSION

1:00-1:20pm    Case 1 – Vascular malformation

Dr. Joyce Castillo

Case 2- Congenital melanocytic nevus

Dr. Jocel Buensalido

Case 3- Nevus sebaceous

Dr. Pamela Guiang

Case 4-Nevus of Hori

Dr. Elieza Dela Cerna

1:20-2:00PM   Reaction to Cases by  Dr. Annette Wagner

2:00-5:00pm    Hands- on Workshop by Dr. Annette M. Wagner

5:00pm             Closing Remarks: Dr. Donna Leelin-Sarrosa

Moderators: Dr. Valerie Floro-Herbosa Dr. Ma. Lourdes Aragon-De Veyra
———————————————————————————————-

PEACHY PAZ LAO, MD
Chairman

Valerie Floro-Herbosa, MD
Residency Training Program Director

CONSULTANT  STAFF

Vermen M. Verallo-Rowell, M.D.
Thelma De Villa-Leelin, M.D.
Filomena Legarda-Montinola, M.D.
Manuel O. Fernandez, M.D.
Imelda Cabral-Villar, M.D.
Esther C. Leynes, M.D.
Elsie P. Floreza, M.D., MSc
Ma. Victoria C. Dizon, M.D.
Donna Marie Leelin-Sarrosa, M.D.
Ma. Lourdes Aragon-de Veyra, M.D.
Ma. Teresa A. Belmonte, M.D.
Lucia O. Castro-Fores, M.D.
Jose Giovanni E. Dimayuga, M.D
Elvira H. Esguerra, M.D.
Rowena Flores-Genuino, M.D..
Sheila Hautea-Pagdanganan, M.D.
Jasmin J. Jamora, M.D.
Carmela Ana V. Lim, M.D.
Mary Anne Luciano-Amon, M.D.
Ma. Patricia F. Astorga-Chavez, M.D.
Giselle Mary Lazaro, M.D.
Stephen F. Lacson, M.D.
Patricia Ty-Tinio, M.D.
Beatriz Carpo, M.D.
Ma. Teresa E. Dimagiba, M.D.
Sherwin llego, M.D.

Visiting Cosultants

Guia R. Avecilla, MD
Marivic Cabillos, MD
Julie P. Delos Santos, MD
Krissinda D. Jamora,MD
Claudine L. Javier,MD
Celia  Theresa L.Layson,MD
Carmencita Salud,MD
Mylah A. Joven,MD
Leah D. Martires,MD
Patricia Valle-Tin,MD

Residents

Chief Resident:
Elieza Marie A. Dela Cerna,MD

Deputy Chief Resident:
Pamela C. Guiang,MD
Jocel S. Buensalido,MD
Joyce Castillo,MD
Margarita Durano,MD
Aileen M. Eduvas,MD
Katrina M.Canlas,MD
Frederica Veronica Protacio,MD
Sarah Tan,MD

8:00-8:30 Invocation
Dr. Marie Judith Eusebio

National Anthem

Opening Remarks
Dr. Arsenia A. Grey

8:30-9:00 Echoes- ISD
Dr. Arlene Sauña

9:00-9:45
Novel Treatment of Keloids
Dr. Abigail Co

Using 5- FU Injection
Demo/ Workshop

9:45-10:00 - Coffee Break

10:00-11:30
Management of Scars
Dr. Stephen Lacson

Demo/ Workshop

11:30-1:20 STIEFEL

1:20-2:00
Lipocurettage
Dr. Krisinda Dim-Jamora
(lecture and video presentation)

2:00-2:30
Lecture on PRP
Dr. Claudia Samonte

2:30-3:00
Lecture on Surgiwire
Dr. Claudia Samonte

3:00-4:00 Demo/ Workshop

MODERATOR: Dr. Lizelle L. Buenafe

4:00-4:10
Closing Remarks
Dr. Evelyn Chan- Aparte